{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:11:32Z","timestamp":1779282692115,"version":"3.51.4"},"reference-count":30,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Torn\u00f8es og H\u00f8yrups Fond","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100031088","name":"Kornerup Fonden","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100031088","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The National Board of Health","award":["4-1612-236\/6"],"award-info":[{"award-number":["4-1612-236\/6"]}]},{"name":"CytoVac A\/S, H\u00f8rsholm, Denmark","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100005747","name":"A.P. M\u00f8ller og Hustru Chastine Mc-Kinney M\u00f8llers Fond","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100005747","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"crossref","award":["A18198"],"award-info":[{"award-number":["A18198"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007403","name":"Dagmar Marshalls Fond","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100007403","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Region of Southern Denmark Research Council","award":["A1047"],"award-info":[{"award-number":["A1047"]}]},{"DOI":"10.13039\/501100010347","name":"Fabrikant Einar Willumsens Mindelegat","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100010347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010346","name":"Else og Mogens Wedell Wedellsborgs Fond","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100010346","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010351","name":"Grosserer M. Brogaard og Hustrus Mindefond","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100010351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,11,13]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adoptive cell transfer-based immunotherapy holds promise for treating advanced cancer. However, a key challenge remains: generating sufficient numbers of lymphocytes capable of recognizing and targeting a broad range of cancer antigens. We recently developed Autologous Lymphoid Effector Cells Specific Against Tumor (ALECSAT), a novel procedure for selecting, expanding and maturing polyclonal lymphocytes from peripheral blood with the capacity to target cancer cells. In this single-center phase Ib trial, we evaluated the safety, tolerability, and preliminary efficacy of ALECSAT in combination with standard carboplatin and gemcitabine in patients with locally advanced or metastatic triple-negative breast cancer (mTNBC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This clinical study enrolled 15 patients with mTNBC. The patients received three ALECSAT doses, administered every 28 days. Subsequently, ALECSAT doses were given at 6-week intervals. Carboplatin and gemcitabine were administered on days 1 and 8 in 3-week cycles. The cell composition of ALECSAT preparations was analyzed using flow cytometry. Additionally, patient-derived xenograft (PDX) mouse models were generated and treated with ALECSAT to assess treatment responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>14 patients with mTNBC, who had received one to four prior treatment lines, were treated with 1\u201310 doses of ALECSAT. The combination of ALECSAT with carboplatin and gemcitabine was well tolerated and demonstrated a favorable safety profile. Common adverse events (AEs), including fatigue, nausea, and hematological abnormalities, were consistent with the known toxicity profiles of carboplatin and gemcitabine. Notably, grade \u22653 AEs were predominantly hematological, with manageable durations of neutropenia and thrombocytopenia. Among treated patients, one achieved a complete response, four had partial responses, five had stable disease, and four had progressive disease. The objective response rate was 36% (95% CI 12.8% to 64.9%). Median progression-free survival was 4.3 months (95%\u2009CI 1.6 to 7.0), while median overall survival was 8.7 months (95%\u2009CI 5.1 to 12.4). A positive correlation was observed between the total number of administered ALECSAT cells (particularly CD8+T cells) and time to progression. Additionally, ALECSAT treatment outcomes in patients correlated with responses observed in their corresponding PDX models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ALECSAT, in combination with carboplatin and gemcitabine, was safe, well tolerated, and demonstrated promising antitumor activity in mTNBC. These findings support further investigation in larger clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00891345\">NCT00891345<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-012213","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T19:10:17Z","timestamp":1764875417000},"page":"e012213","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with chemotherapy in locally advanced or metastatic triple-negative breast cancer: the ImmunoBreast phase Ib clinical trial"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct00891345","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00891345","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5911-7276","authenticated-orcid":false,"given":"Odd Lilleng","family":"Gammelgaard","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidse","family":"Ehmsen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Odense University Hospital, Odense, Denmark"},{"name":"Department of Clinical Research, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Marie Bak","family":"Jylling","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Southern Denmark, Odense, Denmark"},{"name":"Department of Pathology, Odense University Hospital, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene","family":"Sandberg","sequence":"additional","affiliation":[{"name":"Department of Oncology, Odense University Hospital, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexei F","family":"Kirkin","sequence":"additional","affiliation":[{"name":"Cytovac A\/S, H\u00f8rsholm, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0515-9144","authenticated-orcid":false,"given":"Annette Raskov","family":"Kodahl","sequence":"additional","affiliation":[{"name":"Department of Oncology, Odense University Hospital, Odense, Denmark"},{"name":"Department of Clinical Research, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3927-5135","authenticated-orcid":false,"given":"Henrik J","family":"Ditzel","sequence":"additional","affiliation":[{"name":"Department of Oncology, Odense University Hospital, Odense, Denmark"},{"name":"Departments of Molecular Medicine and Clinical Research, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"2026052005400834000_13.12.e012213.1","doi-asserted-by":"crossref","first-page":"vi46","DOI":"10.1093\/annonc\/mds195","article-title":"Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents","volume":"23 Suppl 6","author":"Andr\u00e9","year":"2012","journal-title":"Ann Oncol"},{"key":"2026052005400834000_13.12.e012213.2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-4080-9"},{"key":"2026052005400834000_13.12.e012213.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.010"},{"key":"2026052005400834000_13.12.e012213.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.016"},{"key":"2026052005400834000_13.12.e012213.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.2984"},{"key":"2026052005400834000_13.12.e012213.6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30904-x"},{"key":"2026052005400834000_13.12.e012213.7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of Triple-Negative Breast Cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Annu Rev Pathol"},{"key":"2026052005400834000_13.12.e012213.8","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-018-1002-1","article-title":"Classification of triple-negative breast cancers based on Immunogenomic profiling","volume":"37","author":"He","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"2026052005400834000_13.12.e012213.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9"},{"key":"2026052005400834000_13.12.e012213.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"2026052005400834000_13.12.e012213.11","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30689-8"},{"key":"2026052005400834000_13.12.e012213.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"2026052005400834000_13.12.e012213.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"2026052005400834000_13.12.e012213.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2560"},{"key":"2026052005400834000_13.12.e012213.15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41563-018-0094-5","article-title":"Adoptive T cell cancer therapy","volume":"17","author":"Dzhandzhugazyan","year":"2018","journal-title":"Nat Mater"},{"key":"2026052005400834000_13.12.e012213.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-018-2484-0"},{"key":"2026052005400834000_13.12.e012213.17","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12132"},{"key":"2026052005400834000_13.12.e012213.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2026052005400834000_13.12.e012213.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2026052005400834000_13.12.e012213.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"key":"2026052005400834000_13.12.e012213.21","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2024.07.723","article-title":"Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis","volume":"35","author":"Mart\u00edn-Lluesma","year":"2024","journal-title":"Ann Oncol"},{"key":"2026052005400834000_13.12.e012213.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210233"},{"key":"2026052005400834000_13.12.e012213.23","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967"},{"key":"2026052005400834000_13.12.e012213.24","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03217-9","article-title":"Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells","volume":"9","author":"Kirkin","year":"2018","journal-title":"Nat Commun"},{"key":"2026052005400834000_13.12.e012213.25","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01914-8","article-title":"Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis","volume":"23","author":"Gammelgaard","year":"2024","journal-title":"Mol Cancer"},{"key":"2026052005400834000_13.12.e012213.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2026052005400834000_13.12.e012213.27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx416"},{"key":"2026052005400834000_13.12.e012213.28","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq4617","article-title":"Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance","volume":"8","author":"Ma\u00f1as","year":"2022","journal-title":"Sci Adv"},{"key":"2026052005400834000_13.12.e012213.29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"2026052005400834000_13.12.e012213.30","doi-asserted-by":"crossref","DOI":"10.21037\/sci-2022-029","article-title":"An autologous humanized patient-derived xenograft (PDX) model for evaluation of nivolumab immunotherapy in renal cell cancer: a case report","volume":"9","author":"Kang","year":"2022","journal-title":"Stem Cell Investig"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:40:19Z","timestamp":1779280819000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,4]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/jitc-2025-012213"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012213","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}